EBCC 2024 | Immunotherapy biomarkers in neoadjuvant breast cancer

Jean-Yves Pierga, MD, Institut Curie, Paris, France, comments on the current biomarkers of neoadjuvant immunotherapy efficacy in patients with breast cancer. Whilst PD-L1 has been effective as a biomarker of response in patients with metastatic triple-negative breast cancer (TNBC), it has not been as efficient in the neoadjuvant setting. Alternate biomarkers are needed to identify patients who will benefit from neoadjuvant immunotherapy. This interview took place at the 14th European Breast Cancer Conference (EBCC) in Milan, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.